Comparative Pharmacology
Head-to-head clinical analysis: ENSTILAR versus HALOBETASOL PROPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENSTILAR versus HALOBETASOL PROPIONATE.
ENSTILAR vs HALOBETASOL PROPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ENSTILAR is a combination of calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid). Calcipotriene binds to vitamin D receptors, modulating cell proliferation and differentiation. Betamethasone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply to affected area once daily for up to 4 weeks. Maximum 100 g/day or 30 g/week. Not for use on face, axillae, or groin.
Topical: Apply a thin film to affected areas twice daily (morning and evening). Maximum weekly dose should not exceed 50 g/week. Duration of therapy should be limited to 2 consecutive weeks.
None Documented
None Documented
Calcipotriol: terminal half-life ~12 hours. Betamethasone dipropionate: terminal half-life ~16-22 hours. Clinically, this supports once-daily application.
Terminal elimination half-life is approximately 15-20 hours following topical application, though systemic absorption is minimal with intact skin. Prolonged half-life may occur with extensive use or impaired hepatic function.
Calcipotriol is primarily excreted via bile/feces (approximately 70% of absorbed dose). Betamethasone dipropionate is mainly excreted renally (60-70% as metabolites) and up to 20-30% via feces. For the combination, renal excretion of betamethasone metabolites predominates, with fecal excretion of calcipotriol.
Primarily renal excretion of metabolites (approximately 60-70%) with biliary/fecal elimination accounting for 20-30%. Less than 5% excreted as unchanged drug in urine.
Category C
Category A/B
Topical Corticosteroid and Vitamin D Analog
Topical Corticosteroid